Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

41. Glutamate modulators in treatment of schizophrenia

Glutamate modulators in treatment of schizophrenia Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2019 PROSPERO

42. Risk of psychotic relapse after successful ECT in patients with schizophrenia a systematic review and meta-analysis

Risk of psychotic relapse after successful ECT in patients with schizophrenia a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

43. Quetiapine dose for people with schizophrenia [Cochrane protocol]

Quetiapine dose for people with schizophrenia [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2019 PROSPERO

44. Risk and protective factors associated with relapse in schizophrenia: a systematic review

Risk and protective factors associated with relapse in schizophrenia: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

45. Resting state and diffusion tensor imaging in treatment resistant schizophrenia: a review

Resting state and diffusion tensor imaging in treatment resistant schizophrenia: a review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

46. Safety of risperidone in schizophrenia and bipolar disorder diagnosed patients - a systematic review and meta-analysis

Safety of risperidone in schizophrenia and bipolar disorder diagnosed patients - a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

47. Attentional biases to emotional information in schizophrenia: a systematic review

Attentional biases to emotional information in schizophrenia: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

48. Mindfulness-based interventions for people with schizophrenia: a meta-analysis

Mindfulness-based interventions for people with schizophrenia: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

49. Long term effects of low-frequency repetitive transcranial magnetic stimulation in schizophrenia patients with auditory verbal hallucinations: a meta-analysis

Long term effects of low-frequency repetitive transcranial magnetic stimulation in schizophrenia patients with auditory verbal hallucinations: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

50. Association between schizophrenia and risk of sexual dysfunction: a meta-analysis

Association between schizophrenia and risk of sexual dysfunction: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

51. Olanzapine versus placebo for people with schizophrenia [Cochrane protocol]

Olanzapine versus placebo for people with schizophrenia [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

52. Olanzapine dose for people with schizophrenia [Cochrane protocol]

Olanzapine dose for people with schizophrenia [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2019 PROSPERO

53. NAA in schizophrenia, first episode psychosis and high risk mental state: a systematic review and meta-analysis of proton magnetic resonance studies

NAA in schizophrenia, first episode psychosis and high risk mental state: a systematic review and meta-analysis of proton magnetic resonance studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

54. Pharmacological interventions for reduction of weight gain in people with schizophrenia [Cochrane protocol]

Pharmacological interventions for reduction of weight gain in people with schizophrenia [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

55. Pharmacological interventions for prevention of weight gain in people with schizophrenia [Cochrane protocol]

Pharmacological interventions for prevention of weight gain in people with schizophrenia [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

56. Pharmacogenomics of antipsychotic response: a systematic review and meta-analysis of polygenic risk scores for schizophrenia

Pharmacogenomics of antipsychotic response: a systematic review and meta-analysis of polygenic risk scores for schizophrenia Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

57. A systematic review and meta-analysis: post-mortem hippocampal subfield volume, neuronal number, and neuronal density in schizophrenia and control subjects

A systematic review and meta-analysis: post-mortem hippocampal subfield volume, neuronal number, and neuronal density in schizophrenia and control subjects Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

58. Neural correlates of theory of mind and empathy in schizophrenia: an activation likelihood estimation meta-analysis

Neural correlates of theory of mind and empathy in schizophrenia: an activation likelihood estimation meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

59. Hypothalamic-pituitary-adrenal axis related genes and cognition in major mood disorders and schizophrenia: a systematic review

Hypothalamic-pituitary-adrenal axis related genes and cognition in major mood disorders and schizophrenia: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

60. Meta-analysis of structural magnetic resonance imaging findings in people at ultra-high risk of psychosis, first-episode psychosis or established schizophrenia

Meta-analysis of structural magnetic resonance imaging findings in people at ultra-high risk of psychosis, first-episode psychosis or established schizophrenia Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO